• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Combination treatment with calcineurin inhibitors and IL-2 enhances transplant survival [PreClinical]

byCorinne FoleyandJessica Lau
July 7, 2017
in Chronic Disease, Gastroenterology, Preclinical, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Blood from liver transplant patients treated with a calcineurin inhibitor (CNI) showed increased levels of apoptotic regulatory T cells (Tregs) and lower IL-2 levels.

2. In mice that received skin allografts, combined treatment of a CNI and IL-2 enhanced transplant survival.

Evidence Rating Level: 2 (Good)

Study Rundown: CNIs are currently used to reduce organ transplant rejection and act by suppressing immune cell activation. Despite the effectiveness of this therapy, it is known to reduce levels of Tregs, an immune cell subset involved in suppressing effector T cell responses. Through evaluating the mechanism leading to decreased Tregs, the researchers in this study aimed to revert this effect to increase immunosuppression and reduce transplant rejection.

Liver transplant patients receiving the CNI tacrolimus.were found to have a decrease in Tregs compared to healthy controls as well as an increase in activated Tregs undergoing apoptosis. These patients were also found to have a decrease in circulating IL-2. When blood samples from patients were treated in vitro with tacrolimus and IL-2, there was an increase in Treg frequency and decreased apoptosis. When tested in a skin allograft mouse model, the combination therapy of tacrolimus and IL-2 led to an increase in Treg cell number, as well as significantly increased allograft survival.

The administration of IL-2 in conjunction with CNI therapy was found to enhance immunosuppression and graft acceptance. Since low-dose IL-2 therapy is currently used clinically, its safety has been characterized. Although the safety and efficacy of this combination therapy still needs to be assessed in humans, this study demonstrates its potential as an immunosuppression therapy for transplant recipients.

Click here to read the study in PNAS

RELATED REPORTS

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis

Medical cannabis provides little improvement to sleep in chronic pain patients

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

Relevant Reading: Calcineurin inhibitors and immunosuppression – a tale of two isoforms

In-Depth [animal study]: Blood samples were obtained from liver transplant patients receiving tacrolimus and age-matched healthy individuals. Flow cytometry revealed a lower frequency of CD4+CD25+FOXP3+ Tregs (p< 0.0001) in patient samples. Samples from liver transplant patients also showed higher levels of Tregs undergoing apoptosis, as measured by the marker annexin V (p<0.0001). An ELISA was then used to evaluate IL-2 levels in the serum of transplant patients, and showed that levels were significantly decreased (p<0.05). When blood cells from transplant patients were treated with clinically relevant concentrations of tacrolimus and recombinant IL-2 (rIL-2), the reduction in Treg numbers and increase in Treg apoptosis were reversed (p<0.001).

After mice were treated with tacrolimus, with or without the addition of IL-2, a whole genome microarray was used to evaluate gene transcriptional differences. This analysis showed that tacrolimus reduced the expression of genes essential for Treg function. With the addition of IL-2, however, there were few changes in the expression of Treg functional genes compared to control.

Finally, to determine whether IL-2 improves graft acceptance, B6 mice were transplanted with skin grafts from BALB/c mice. The combination therapy of tacrolimus and IL-2 was found to significantly increase the survival of the skin graft, whether IL-2 was administered initially with tacrolimus or at the end of tacrolimus treatment (p<0.05). Combination treatment increased Treg frequency in the blood, lymph nodes, and allografts of these mice (p< 0.001).

Image: PD

 

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Demand for FMT likely to increase with rise in multiply recurrent C. difficile cases

Next Post

Metformin treats Fragile X syndrome symptoms in mice [PreClinical]

RelatedReports

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
StudyGraphics

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis

May 27, 2022
Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

Medical cannabis provides little improvement to sleep in chronic pain patients

May 27, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

May 26, 2022
#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
StudyGraphics

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly

May 26, 2022
Next Post
Metformin treats Fragile X syndrome symptoms in mice [PreClinical]

Metformin treats Fragile X syndrome symptoms in mice [PreClinical]

Adalimumab use results in high clinical response rate in hidradenitis suppurativa

Homozygous complement component CD55 mutations cause novel gastrointestinal syndrome

Missed or misinterpreted neuroradiologic findings by trainees at an academic medical center

Radiofrequency denervation not effective in chronic low back pain

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.